To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
VC-backed Foghorn Therapeutics goes public
Cambridge, Massachusetts-based Foghorn Therapeutics, a developer of therapies for cancer and other serious diseases, has raised about $120 million for its IPO after pricing its 7.5 million shares at $16 per share.
